The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma-Reference-Cited by-同舟云学术

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

Published:2019-07 Issue:9 Volume:74 Page:1716-1726
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Chapman Kenneth R.¹,Albers Frank C.²^ORCID,Chipps Bradley³,Muñoz Xavier⁴⁵,Devouassoux Gilles⁶,Bergna Miguel⁷,Galkin Dmitry²,Azmi Jay⁸,Mouneimne Dalal⁹,Price Robert G.¹⁰,Liu Mark C.¹¹

Affiliation:

1. Asthma and Airway Centre University Health Network, University of Toronto Toronto Ontario Canada

2. Global Respiratory Medical Franchise GSK Research Triangle Park North Carolina

3. Capital Allergy and Respiratory Disease Center Sacramento California

4. Pulmonology Department Hospital Universitari Vall d'Hebron Barcelona Spain

5. Ciber Enfermedades Respiratorias Madrid Spain

6. Service de Pneumologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon UCB Lyon 1 Lyon France

7. Respiratory Research CEMER, Vicente Lopez Buenos Aires Argentina

8. Respiratory TAU GSK Uxbridge UK

9. Global Medical Affairs GSK House Brentford Middlesex UK

10. Clinical Statistics GSK Stevenage UK

11. Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine Johns Hopkins Asthma and Allergy Center Baltimore Maryland

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.13850

Reference35 articles.

1. WHO.Asthma fact sheet.2017;http://www.who.int/mediacentre/factsheets/fs307/en/. Accessed January 10 2018.

2. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

3. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

4. Current and emerging treatments for severe asthma;Al Efraij K;J Thorac Dis.,2015

5. Severe asthma: from characteristics to phenotypes to endotypes

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics;Respiratory Medicine;2024-11

2. Choosing the right biologic treatment for individual patients with severe asthma – Lessons learnt from Picasso;Respiratory Medicine;2024-11

3. Role of IL‐5 in asthma and airway remodelling;Clinical & Experimental Allergy;2024-06-27

4. Expert opinion on diagnosis and management of Severe Asthma in low and middle income countries (LMIC) with focus on India;Journal of Asthma;2024-06-19

5. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme;European Respiratory Journal;2024-04-04